Back to Peptide Pedia
Cognitive & Nootropic
Emerging Research

PE-22-28

PE-22

TREK-1 channel blocker studied in mood research.

Also known as: Mini-Spadin, Spadin analog

Research dose range200–500 mcg (research models)
Route studiedSubcutaneous / intranasal
Study durationDaily, multi-week studies
Storage2–8 °C reconstituted

Overview

PE-22-28 is a synthetic peptide analog of spadin studied in mood-regulation and neuroplasticity research.

Key research findings

A 7-amino-acid fragment of the neuroprotective protein spadin, studied as a TREK-1 potassium-channel blocker. Because TREK-1 inhibition is a proposed fast-acting antidepressant mechanism, research interest centers on rapid mood effects and neuroplasticity.

Mechanism of action

Studied for blocking the TREK-1 potassium channel, a target investigated in fast-acting mood-modulation research.

Molecular information

Weight~750 Da
Length7 amino acids
TypeSpadin-derived TREK-1 channel blocker

Derived from the propeptide of sortilin (spadin); targets the TREK-1 background K+ channel.

Pharmacokinetics

Peak: ~0.5 hoursHalf-life: ~Short (hours)Cleared: ~24 hours
Peak · 1hHalf-life · 5h

Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.

Research applications

  • Mood-regulation research
  • Neuroplasticity studies
  • Ion-channel investigations

Research protocols

Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.

Conservative referenceAmount: 200 mcgFrequency: Once dailyRoute: Subcutaneous
Standard referenceAmount: 500 mcgFrequency: Once dailyRoute: Subcutaneous

Observed effects timeline

Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.

  1. Acute–Week 1

    Mood and neuroplasticity signaling reported relatively rapidly in study models (TREK-1 mechanism).

  2. Week 2–4

    Antidepressant-like and neuroplastic changes reported with continued use.

Research compatibility

Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.

Semax

Complementary BDNF/neuroplasticity pathways.

Compatible

Selank

Complementary mood/anxiolytic mechanisms.

Compatible

DSIP

Distinct neuropeptide pathways.

Compatible

How to reconstitute

Important

Reconstitute with bacteriostatic water, swirl gently, and refrigerate. Avoid shaking to preserve the peptide.

  1. 1Allow the vial to reach room temperature (15–20 minutes).
  2. 2Swab the stopper with alcohol and let it air dry.
  3. 3Add bacteriostatic water slowly down the vial wall.
  4. 4Swirl gently until dissolved into a clear solution.
  5. 5Refrigerate at 2–8 °C and protect from light.
Open reconstitution calculator

Quality indicators

Uniform white powder

Lyophilized cake should be white to off-white without discoloration.

Clear solution

Reconstitutes to a clear, colorless, particle-free solution.

Cold-chain integrity

Reconstituted solution requires 2–8 °C storage.

Slight clumping

Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.

Collapsed or melted appearance

Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.

Cloudy after reconstitution

Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.

Reported observations & safety

Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.

  • Human data are essentially absent; evidence is preclinical and the peptide is experimental.
  • The TREK-1 mechanism is of high research interest for fast-acting antidepressant pathways.

References & further reading

Spadin and PE 22-28: TREK-1 inhibition and antidepressant effects (preclinical)

PreclinicalTREK-1antidepressant

Research on spadin-derived peptides blocking TREK-1 channels and producing antidepressant-like effects.

View study

Topics

moodtrek-1neuroplasticity

This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.

Research level
Emerging Research

Active but early-stage research; evidence still developing.

Quick reference
Dose range200–500 mcg (research models)
RouteSubcutaneous / intranasal
DurationDaily, multi-week studies
Storage2–8 °C reconstituted
Half-life~Short (hours)
Catalogue status

This compound is part of our educational reference and is not currently stocked. Browse the catalogue for available research-grade peptides.

Browse catalogue